InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

Current share price for PAR : $0.178 0.003 (1.43%)+

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$106 Paradigm OA Phase 2b Clinical Trial over 80% Recruited 17 May 2018 8:56AM $0.470 $0.178 fallen by 62.23%
$106 Change of Director's Interest Notice 8 May 2018 2:02PM $0.410 $0.178 fallen by 56.71%
$106 Cleansing Notice 8 May 2018 9:59AM $0.400 $0.178 fallen by 55.63%
$106 Appendix 3B 7 May 2018 7:04PM $0.400 $0.178 fallen by 55.63%
$106 Appendix 4C - quarterly 30 Apr 2018 8:21AM $0.380 $0.178 fallen by 53.29%
$106 PAR Non-Deal Roadshow Presentation 17 Apr 2018 9:38AM $0.365 $0.178 fallen by 51.37%
$106 Corporate Governance Statement 13 Apr 2018 5:25PM $0.330 $0.178 fallen by 46.21%
$106 PARADIGMs PHASE 2 CLINICAL DATA UPDATE 27 Mar 2018 10:05AM $0.290 $0.178 fallen by 38.79%
$106 PARADIGM REPORTS OSTEOARTHRITIS PAIN REDUCED BY 50% 1 Mar 2018 8:18AM $0.300 $0.178 fallen by 40.83%
$106 Half Year Accounts 22 Feb 2018 5:30PM $0.275 $0.178 fallen by 35.45%
$106 Quarterly Update and Appendix 4C 30 Jan 2018 10:30AM $0.345 $0.178 fallen by 48.55%
$106 Elite sportspeople successfully treated with PPS 24 Jan 2018 9:55AM $0.325 $0.178 fallen by 45.38%
$106 PARs European Patent Granted for Bone Marrow Edema Lesions 16 Jan 2018 8:31AM $0.340 $0.178 fallen by 47.79%
$106 Paradigm Shareholder Newsletter 20 Dec 2017 1:55PM $0.250 $0.178 fallen by 29%
$106 Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule 23 Nov 2017 8:27AM $0.300 $0.178 fallen by 40.83%
$106 Appendix 3B and Cleansing Notice 16 Nov 2017 5:12PM $0.280 $0.178 fallen by 36.61%
$106 Change in substantial holding 15 Nov 2017 11:10AM $0.300 $0.178 fallen by 40.83%
$106 Change of Director's Interest Notice 15 Nov 2017 11:03AM $0.300 $0.178 fallen by 40.83%
$106 Cleansing Notice - Section 708A 15 Nov 2017 9:46AM $0.305 $0.178 fallen by 41.80%
$106 Paradigms ACL Phase 2 Clinical Trial Success 14 Nov 2017 8:38AM $0.300 $0.178 fallen by 40.83%
$106 Appendix 3B 13 Nov 2017 4:56PM $0.300 $0.178 fallen by 40.83%
$106 Results of Meeting 10 Nov 2017 12:40PM $0.330 $0.178 fallen by 46.21%
$106 CEO Update 10 Nov 2017 10:01AM $0.335 $0.178 fallen by 47.01%
$106 PAR Successfully Completes A$5.75m Placement 6 Nov 2017 9:30AM $0.360 $0.178 fallen by 50.69%
$106 Trading Halt 2 Nov 2017 8:53AM $0.360 $0.178 fallen by 50.69%

576 - 600 of 720 results

Page 24 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.